Xijing Hospital

Company snapshot

Xijing Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Melanoma, Multiple Myeloma, Stroke, Thyroid Cancer. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (1).

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Xijing Hospital. Not investment advice.

• What is Xijing Hospital?

  Xijing Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Melanoma, Multiple Myeloma, Stroke, Thyroid Cancer. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Cli

• Is Xijing Hospital publicly traded?

  Xijing Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Xijing Hospital develop or market?

  We link 5 drug profile(s) where Xijing Hospital is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/xijing-hospital#company-drugs.

• What are the latest developments for Xijing Hospital?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Xijing Hospital focus on?

  Xijing Hospital focuses on Melanoma, Multiple Myeloma, Stroke based on our analysis of their pipeline programs and drug development activities.